08/15/2025
Dr. Max Krucoff’s use of Delta T1 maps to assess ablation extent after LITT is a powerful example of how the objective, quantitative imaging of Delta T1 maps can elevate clinical decision-making and confidence.
Unlike conventional image (like T1+C) that rely on subjective interpretation, Delta T1 maps remove ambiguity—delivering reproducible insights that support better outcomes.
Proud to see Imaging Biometrics’ technology helping clinicians push the boundaries of neuro-oncology!
